Long-term use of sildenafil

Bibliography

• NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA (1995) 270:83–90.
   Google Scholar
• FELDMAN AH, GOLDSTEIN I, HATZICHRISTOU DG et al: Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study.' Um]. (1994) 151:54–61.
   Google Scholar
• CARSON CC, WEST SL, GLASSER DB et al.: Prevalence and correlates of erectile dysfunction. A United States nationwide population base sample: Phase I results. .1 Urol (2002) 167:29.
   Google Scholar
• DERBY CA, MOHR BA, GOLDSTEIN I et al.: Modifiable risk factors and erectile dysfunction: can a lifestyle change modify risk? Urology (2000) 56:302–306.
   Google Scholar
• BENET AE, MELMAN A:The epidemiology of erectile dysfunction. Uro] Clin. North Am. (1975) 2:699–709.
   Google Scholar
• Contemporary Urology 2002–2003 Fact Book Thompson Medical Economics, NJ, USA (2002):46.
   Google Scholar
• TELOKEN C, RHODEN E, SOGARI P et al.: Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. Urol (1998) 159:122–124.
   Google Scholar
• MORALES A, CONDRA M, OWEN J et al.: Is yohimbine effective in the treatment of organic impotence? J. Urol (1987) 137:1168–1172.
   Web of Science ®Google Scholar
• SAENZDETEJADA I, WARE JC, BIANCO R et al.: Pathophysiology of prolonged penile erection associated with trazodone use. .1 Um]. (1991) 145:60–64.
   Google Scholar
• CARSON CC, MINO RD: Priapism associated with trazodone therapy. J. Urol (1988) 139:369–370.
   PubMed Web of Science ®Google Scholar
• ZORGNIOTTI A, LIZZA E: Effective large doses of the NO precursor L-arginine on erectile function. Int. .1 Impot. Res. (1994) 6:33–35.
   PubMedGoogle Scholar
• CHEN J, WOLLMAN Y, CHERNICHOVSKY T, IAINA A, SOFER M, MATZKIN H: Effective oral administration of high dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double blind randomized placebo controlled study. BJU. mt. (1999) 83:269–271.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN I, CARSON CC, ROSEN R, ISLAM A: Vasomax for the treatment of male erectile dysfunction. World J. Um]. (2001) 19:51–56.
   PubMedGoogle Scholar
• HEATON JLM: Key issues from the clinical trials of apomorphine SL. World J. Uro] (2001) 19:25–31.
   PubMedGoogle Scholar
• CORBIN JD, FRANCIS SH, WEBB DJ: Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology (2002) 60(Suppl. 2B):4–11.
   Google Scholar
• KRANE R, BROCK G, EARDLEY I et al: Oral non endocrine treatment. In: Erectile Dysfunction: First International Consultation on Erectile Dysfunction. Jardin A, Wagner G, Khoury S et al. (Eds) Health Publication Limited, Plymouth, UK (2000):258–261.
   Google Scholar
• MORELAND RB, GOLDSTEIN I, TRAISH A: Sildenafil: a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci. (1998) 62:PL309-PL318.
   Google Scholar
• GOLDSTEIN I, LUE T, PADMA-NATHAN H et al.: Oral sildenafil in the treatment of erectile dysfunction. N. Eng] J. Med. (1998) 338:1397–1404.
   PubMed Web of Science ®Google Scholar
• PADMA-NATHAN H, STEERS WD, WICKER PA: Efficacy and safety of oral sildenafil and the treatment of erectile dysfunction: a double blind placebo controlled study of 329 patients. Int. J. Clin. Proc. (1998) 53:1–4.
   Google Scholar
• NICHOLS DJ, MUIRHEAD GJ, HARNESS JA: Pharmacogenetics of sildenafil after single oral doses in healthy male subjects: absolue bioavailability, food effects, and dose proportionality. Br. J. Clin. Pharmacol (2002) 53:5S–12S.
   Google Scholar
• WALKER DK, ACKLAND MJ, JAMES GC et al: Pharmacolkinetics and metabolism of sildenafil in mouse, rat, rabbit, dog, and man. Xenobiotica (1999) 29:297–310.
   PubMed Web of Science ®Google Scholar
• MUIRHEAD GJ, ALLEN MJ, JAMES GC et al.: Pharmacolkinetics of sildenafil, a selective cGMP PDE 5 inhibitor, after single oral doses in fasted and fed healthy volunteers. Br: J. Clin. Pharmacol (1996) 42:268P.
   Google Scholar
• MUIRHEAD GJ, RONCE DJ,WALKER DK, WASTOLL P: Comparative human pharmacolkinetics and metabolism of a single dose oral and intravenous sildenafil citrate. J. Clin. Pharm. (2002) 53(Suppl.):135–215.
   Google Scholar
• JACKSON G: Phosphodiesterase 5 inhibition effects on the coronary vasculature. Int. J. Clin. Pract. (2001) 55:183–188.
   PubMed Web of Science ®Google Scholar
• CHIANG CE, LUK HN, WANG TM, DING PY: Effects of sildenafil on cardiac repolarization. Cardiovasc. Res. (2002) 55:290–299.
   PubMedGoogle Scholar
• GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Sildenafil for treatment of lung fibrosis in pulmonary hypertension: a randomized controlled trial. Lancet (2002) 360:895–900.
   PubMed Web of Science ®Google Scholar
• WALLIS RM, CORBIN JD,FRANCIS SH, ELLIS P: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissues cyclic nucleotides, platelet function in the contractile responses of trabeculate carneae in aortic rings in vitro. Am. J. Carcliol. (1999) 83(5A):3C–12C.
   Google Scholar
• HERMANN HC, CHANG G, KLUGHERZ BD et al.: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Eng] J. Med. (2000) 342:1622–1626.
   PubMedGoogle Scholar
• JACKSON G, BENJAMIN N, JACKSON N et al.: Effects of sildenafil citrate on human hemodynamics. Am. J. Cardiol (1999) 83(Suppl. 5413C–20C.
   Google Scholar
• LATIES A, ELLIS P, MOLLON JD: The effects of sildenafil citrate on color discrimination in volunteers and patients with erectile dysfunction. Invest. Ophthalmol Vis. Sci. (1999) 40:S693.
   Google Scholar
• MUIRHEAD GJ, WILNER K,COLBURN W et al.: The effects of age and renal and hepatic impairment on the pharmacolkinetics of sildenafil citrate. Br. J. Pharmacol (2002) 53:215–305.
   Google Scholar
• PRICKAERTS J, VAN STAVERN WC, SIK A et al: Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience (2002) 113(2):351–361.
   PubMed Web of Science ®Google Scholar
• OCKAILI R, SALLOUM F, HAWKINS J et al.: Sildenafil induces powerfulcardio protective effect via opening of mitochondrial K(ATP) channels in rabbits. Am. J. Physiol Heart Circ. Physiol (2002) 283:H1263–H1269.
   Google Scholar
• CARSON CC, BURNETT AL, LEVINE LA, NEHRA A: The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology (2002) 60(Suppl. 2B):12–27.
   Google Scholar
• BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active type 5cyclic GMP specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. (1996) 8:47–52.
   PubMedGoogle Scholar
• PADMA-NATHAN h, EARDLEY I, KLONER RA et al.: A four year update on the safety of sildenafil. Urology (2002) 60(Suppl. 2B):67–90.
   Google Scholar
• MORALES A, GINGELL C, COLLINS M et al.: Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. J. Impot. Res. (1998) 10:69–74.
   PubMed Web of Science ®Google Scholar
• CARSON CC, SIEGEL RL, ORAZEM J: Sildenafil citrate treatment for erectile dysfunction: rate of adverse events decreases with time. J. Urol. (2002) 167(Suppl.):179.
   Google Scholar
• CHEITLIN MD, HUTTER AM Jr, BRINDIS RG et al: ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College ofCardiology/American Heart Association. J. Am. Coll. Cardiol (1999) 33:273–283.
   PubMed Web of Science ®Google Scholar
• MCCULLOUGH AR, BARADA JH, FAWZY A et al.: Achieving treatment optimization with sildenafil citrate in patients with erectile dysfunction. Urology (2002) 60(Suppl. 2B):28–38.
   Google Scholar
• ROSEN RC, RILEY A, WAGNER G et al.: The International Index for Erectile Function (IIEF): a multidimensional scale for assessment of erectile function. Urology (1997) 49:822–830.
   PubMed Web of Science ®Google Scholar
• JAROW JP, BURNETT AL,GERINGER AM: Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. Urol. (1999) 162:722–725.
   Google Scholar
• DERRY F, HULTLING C, SEFATEL AD et al.: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and spinal cord injury: a review. Urology (2002) 60 (Suppl. 2B) :49–57.
   Google Scholar
• YOUNG JM, BENNETT C,GILHOOLY P et al.: Efficacy and safety of sildenafil in Black and Hispanic American men. Urology (2002) 60 (Suppl. 2B):39–48.
   Google Scholar
• NURNBERG HG, SEIDMAN SN, GELENBERG AJ et al.: Depression, anti-depressant therapy in erectile dysfunction: clinical trials of sildenafil citrate in treated and untreated patients with depression. Urology (2002) 60 (Suppl. 2B):58–66.
   Google Scholar
• El GALLEY R, RUTLAND H, TALIC R et al.: Long term efficacy of sildenafil and tachyphylaxis effect. J. Urol. (2001) 166:927–931.
   PubMedGoogle Scholar